Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stake Raised by State Street Corp

State Street Corp boosted its holdings in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 10.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 334,360 shares of the company’s stock after acquiring an additional 30,916 shares during the quarter. State Street Corp’s holdings in Lifecore Biomedical were worth $1,648,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Marshall Wace LLP increased its stake in Lifecore Biomedical by 87.3% in the 2nd quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock valued at $1,540,000 after buying an additional 139,887 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Lifecore Biomedical during the 2nd quarter valued at $327,000. BNP Paribas Financial Markets grew its holdings in shares of Lifecore Biomedical by 2,640.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock valued at $268,000 after acquiring an additional 52,414 shares in the last quarter. Wittenberg Investment Management Inc. increased its stake in shares of Lifecore Biomedical by 287.8% in the third quarter. Wittenberg Investment Management Inc. now owns 57,896 shares of the company’s stock worth $285,000 after acquiring an additional 42,967 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Lifecore Biomedical during the third quarter worth $207,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Craig Hallum boosted their price target on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 22nd.

Lifecore Biomedical Stock Up 0.1 %

LFCR opened at $7.43 on Thursday. Lifecore Biomedical, Inc. has a twelve month low of $3.68 and a twelve month high of $8.90. The business has a 50 day moving average price of $6.96 and a 200 day moving average price of $5.77. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83. The firm has a market cap of $273.62 million, a P/E ratio of 92.88 and a beta of 0.99.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings data on Friday, October 4th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.07). The company had revenue of $24.71 million for the quarter, compared to the consensus estimate of $23.30 million. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. Research analysts forecast that Lifecore Biomedical, Inc. will post -0.99 EPS for the current year.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.